While Regulus was getting dinged this morning following some careful
scrutiny of its latest hep C data, Achillion came out on top with new
trial results which demonstrated that a combination of its NS5A
inhibitor and Gilead's Sovaldi triggered a 6-week cure among all of the
patients in a small study. And now researchers are using the data to set
the stage to see if the results can be replicated even faster in a
Investigators found that 50 mg of ACH-3102 and 400 mg of sofosbuvir
did the trick for 12 out of 12 treatment-naive genotype 1 patients. CEO
Milind Deshpande touted the results as the shortest duration, highest
response results yet seen. He added: "Given the exceptional profile of
ACH-3102, we will now be evaluating four- and six-week treatment
durations that leverage all of our HCV assets including ACH-3102,
ACH-3422, and sovaprevir."
Achillion is still looking to enter a fast-crowding marketplace.
Competing drugs from Gilead and AbbVie have forced out earlier standard
remedies with oral combos that are much easier to tolerate and much more
likely to provide a lasting cure. The goal now is to find ways to do it
quicker and with less expense, providing an opening for some of the
companies still in the hunt.
Labels: 6 week treatment, ACH-3102 plus sofosbuvir, achillion